APA (7th ed.) Citation

Christopoulos, P., Endris, V., Bozorgmehr, F., El Sayed, M., Kirchner, M., Ristau, J., . . . Thomas, M. (2018). EML4-ALK fusion variant V3 is a high-risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in ALK+ non-small cell lung cancer. International journal of cancer, 142(12), . https://doi.org/10.1002/ijc.31275

Chicago Style (17th ed.) Citation

Christopoulos, Petros, et al. "EML4-ALK Fusion Variant V3 Is a High-risk Feature Conferring Accelerated Metastatic Spread, Early Treatment Failure and Worse Overall Survival in ALK+ Non-small Cell Lung Cancer." International Journal of Cancer 142, no. 12 (2018). https://doi.org/10.1002/ijc.31275.

MLA (9th ed.) Citation

Christopoulos, Petros, et al. "EML4-ALK Fusion Variant V3 Is a High-risk Feature Conferring Accelerated Metastatic Spread, Early Treatment Failure and Worse Overall Survival in ALK+ Non-small Cell Lung Cancer." International Journal of Cancer, vol. 142, no. 12, 2018, https://doi.org/10.1002/ijc.31275.